MX2017003216A - Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica. - Google Patents
Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica.Info
- Publication number
- MX2017003216A MX2017003216A MX2017003216A MX2017003216A MX2017003216A MX 2017003216 A MX2017003216 A MX 2017003216A MX 2017003216 A MX2017003216 A MX 2017003216A MX 2017003216 A MX2017003216 A MX 2017003216A MX 2017003216 A MX2017003216 A MX 2017003216A
- Authority
- MX
- Mexico
- Prior art keywords
- antagonists
- progression
- psoriatic arthritis
- structural damage
- inhibit
- Prior art date
Links
- 201000001263 Psoriatic Arthritis Diseases 0.000 title abstract 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 title abstract 3
- 239000005557 antagonist Substances 0.000 title abstract 2
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960004540 secukinumab Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Oncology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462048512P | 2014-09-10 | 2014-09-10 | |
| PCT/IB2015/056871 WO2016038538A1 (en) | 2014-09-10 | 2015-09-08 | Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017003216A true MX2017003216A (es) | 2017-05-23 |
Family
ID=54186247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017003216A MX2017003216A (es) | 2014-09-10 | 2015-09-08 | Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica. |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11278618B2 (enExample) |
| EP (2) | EP3191120B1 (enExample) |
| JP (4) | JP2017528465A (enExample) |
| KR (2) | KR20170045240A (enExample) |
| CN (4) | CN115944734A (enExample) |
| AU (2) | AU2015313827C1 (enExample) |
| BR (1) | BR112017003332A2 (enExample) |
| CA (1) | CA2960754A1 (enExample) |
| DK (1) | DK3191120T3 (enExample) |
| ES (1) | ES2981697T3 (enExample) |
| FI (1) | FI3191120T3 (enExample) |
| HR (1) | HRP20240921T1 (enExample) |
| HU (1) | HUE067081T2 (enExample) |
| LT (1) | LT3191120T (enExample) |
| MX (1) | MX2017003216A (enExample) |
| PL (1) | PL3191120T3 (enExample) |
| PT (1) | PT3191120T (enExample) |
| RS (1) | RS65851B1 (enExample) |
| RU (1) | RU2697383C2 (enExample) |
| SI (1) | SI3191120T1 (enExample) |
| SM (1) | SMT202400285T1 (enExample) |
| WO (1) | WO2016038538A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2960754A1 (en) | 2014-09-10 | 2016-03-17 | Novartis Ag | Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients |
| JP6931648B2 (ja) | 2015-10-27 | 2021-09-08 | ユーシービー バイオファルマ エスアールエル | 抗ｉｌ−１７ａ／ｆ抗体を用いた治療方法 |
| US10676522B2 (en) * | 2017-05-05 | 2020-06-09 | Novartis Ag | Methods of selectively treating asthma using IL-17 antagonists |
| CA3073597A1 (en) * | 2017-08-23 | 2019-02-28 | Eli Lilly And Company | Treatment of genital psoriasis |
| CN111344043A (zh) * | 2017-11-02 | 2020-06-26 | 诺华股份有限公司 | 使用白细胞介素-17(il-17)拮抗剂治疗肌腱病的方法 |
| MA56124A (fr) * | 2019-06-04 | 2022-04-13 | Janssen Biotech Inc | Méthode sûre et efficace de traitement de l'arthrite psoriasique au moyen d'un anticorps spécifique anti-il23 |
| KR102576258B1 (ko) | 2019-12-05 | 2023-09-11 | 아주대학교산학협력단 | 펩타이드 또는 이의 혼합물을 유효성분으로 함유하는 조성물 및 이의 의학적 용도 |
| KR102394378B1 (ko) | 2020-10-14 | 2022-05-03 | 한림대학교 산학협력단 | 피부 각질세포에서의 아릴탄화수소 수용체 억제자(AhRR) 과발현 방법 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0417487D0 (en) * | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| GB0425569D0 (en) | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
| DK1963368T6 (da) | 2005-12-13 | 2020-06-29 | Lilly Co Eli | Anti-il-17-antistoffer |
| JP5068270B2 (ja) | 2006-01-31 | 2012-11-07 | ノバルティス アーゲー | 癌を処置するためのｉｌ−１７アンタゴニスト抗体 |
| GB0612928D0 (en) | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
| US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
| EP2171449A2 (en) | 2007-06-20 | 2010-04-07 | Schering Corporation | Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease |
| US7856118B2 (en) | 2007-07-20 | 2010-12-21 | The Procter & Gamble Company | Methods for recommending a personal care product and tools therefor |
| WO2010034443A1 (en) | 2008-09-29 | 2010-04-01 | F. Hoffmann-La Roche Ag | Antibodies against human il 17 and uses thereof |
| EP2625199B1 (en) * | 2010-10-08 | 2017-11-22 | Novartis AG | Methods of treating psoriasis using il-17 antagonists |
| HRP20251174T1 (hr) * | 2010-11-05 | 2025-11-21 | Novartis Ag | Postupci za liječenje psorijatičnog artritisa uporabom il-17 antagonista |
| WO2012082573A1 (en) * | 2010-12-13 | 2012-06-21 | Novartis Ag | Predictive methods and methods of treating arthritis using il-17 antagonists |
| EP2783014A1 (en) * | 2011-11-21 | 2014-10-01 | Novartis AG | Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non- response alleles |
| CN103936854B (zh) * | 2014-04-30 | 2016-08-17 | 北京精益泰翔技术发展有限公司 | 抗il-17a单克隆抗体及其制备与应用 |
| CA2960754A1 (en) * | 2014-09-10 | 2016-03-17 | Novartis Ag | Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients |
-
2015
- 2015-09-08 CA CA2960754A patent/CA2960754A1/en active Pending
- 2015-09-08 PL PL15767597.6T patent/PL3191120T3/pl unknown
- 2015-09-08 CN CN202210786909.9A patent/CN115944734A/zh active Pending
- 2015-09-08 SI SI201532020T patent/SI3191120T1/sl unknown
- 2015-09-08 HU HUE15767597A patent/HUE067081T2/hu unknown
- 2015-09-08 EP EP15767597.6A patent/EP3191120B1/en active Active
- 2015-09-08 US US15/508,441 patent/US11278618B2/en active Active
- 2015-09-08 CN CN202110368292.4A patent/CN113069542A/zh active Pending
- 2015-09-08 RU RU2017107501A patent/RU2697383C2/ru active
- 2015-09-08 FI FIEP15767597.6T patent/FI3191120T3/fi active
- 2015-09-08 WO PCT/IB2015/056871 patent/WO2016038538A1/en not_active Ceased
- 2015-09-08 KR KR1020177006313A patent/KR20170045240A/ko not_active Ceased
- 2015-09-08 EP EP24169328.2A patent/EP4406969A3/en active Pending
- 2015-09-08 AU AU2015313827A patent/AU2015313827C1/en active Active
- 2015-09-08 HR HRP20240921TT patent/HRP20240921T1/hr unknown
- 2015-09-08 SM SM20240285T patent/SMT202400285T1/it unknown
- 2015-09-08 BR BR112017003332A patent/BR112017003332A2/pt not_active Application Discontinuation
- 2015-09-08 JP JP2017513409A patent/JP2017528465A/ja not_active Withdrawn
- 2015-09-08 PT PT157675976T patent/PT3191120T/pt unknown
- 2015-09-08 DK DK15767597.6T patent/DK3191120T3/da active
- 2015-09-08 MX MX2017003216A patent/MX2017003216A/es unknown
- 2015-09-08 CN CN202210788000.7A patent/CN115957326A/zh active Pending
- 2015-09-08 CN CN201580047920.1A patent/CN107073110A/zh active Pending
- 2015-09-08 LT LTEPPCT/IB2015/056871T patent/LT3191120T/lt unknown
- 2015-09-08 RS RS20240773A patent/RS65851B1/sr unknown
- 2015-09-08 KR KR1020237041277A patent/KR20230170796A/ko active Pending
- 2015-09-08 ES ES15767597T patent/ES2981697T3/es active Active
-
2018
- 2018-02-27 AU AU2018201410A patent/AU2018201410A1/en not_active Abandoned
-
2021
- 2021-05-25 JP JP2021087382A patent/JP7288927B2/ja active Active
-
2022
- 2022-02-15 US US17/672,242 patent/US20220313818A1/en active Pending
-
2023
- 2023-05-29 JP JP2023087736A patent/JP7591092B2/ja active Active
-
2024
- 2024-11-15 JP JP2024199491A patent/JP2025024104A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX384192B (es) | Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma. | |
| MX2017003216A (es) | Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica. | |
| NZ737399A (en) | Ccr2 modulators | |
| PH12017500583B1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| PH12016501830A1 (en) | Inhibitors of c5a for the treatment of viral pneumonia | |
| PH12016501457B1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| EA201692285A8 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
| MX378273B (es) | Compuestos activos hacia bromodominios. | |
| MX2013009679A (es) | Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso. | |
| EP4378536A3 (en) | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | |
| PH12016500094A1 (en) | Autotaxin inhibitors | |
| EA201691582A1 (ru) | Новые фармацевтические препараты | |
| HUE049341T2 (hu) | Szubsztituált indazolok, eljárás ezek elõállítására, ezeket tartalmazó gyógyszerkészítmények, valamint ezek alkalmazása gyógyszerkészítmények elõállítására | |
| HK1251481A1 (zh) | 使用白介素-17(il-17)拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法 | |
| EA201590359A1 (ru) | Лечение ревматоидного артрита | |
| TW201613864A (en) | Novel compounds | |
| AR100944A1 (es) | ANTICUERPOS ANTAGONISTAS DE INTERFERÓN a Y w | |
| MD20170048A2 (ro) | Formulare pe bază de acetat de abirateronă şi procedee de utilizare a acesteia | |
| MX2021010472A (es) | Anticuerpos neutralizantes de gm-csf para usarse en el tratamiento de artritis reumatoide o como analgesicos. | |
| PH12016501686A1 (en) | Pharmaceutical compositions of sitagliptin | |
| PH12017500348A1 (en) | Tetrahydroquinoline derivatives as bromodomain inhibitors | |
| EP4477265A3 (en) | Methods of treating new-onset plaque type psoriasis using il-17 antagonists | |
| HK1216754A1 (zh) | 抗-rankl抗体及其使用方法 | |
| MX371343B (es) | Moduladores del receptor x hepatico (lxr). | |
| MX382918B (es) | Proceso para fabricar partículas de resinato de fenilefrina; partículas de resinato de fenilefrina y uso de las partículas de resinato de fenilefrina en formulaciones farmacéuticas. |